Union européenne - français - EMA (European Medicines Agency)

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - agents antinéoplasiques - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Canada - français - Health Canada

beigene switzerland gmbh - zanubrutinib - capsule - 80mg - zanubrutinib 80mg - antineoplastic agents

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

beigene switzerland gmbh - zanubrutinibum - gélules - zanubrutinibum 80 mg, cellulosum microcristallinum, carmellosum natricum conexum, natrii laurilsulfas, silica colloidalis anhydrica, magnesii stearas, kapselhülle: gelatina, e 171, drucktinte: lacca, e 172 (nigrum), propylenglycolum, pro capsula corresp. natrium 1.17 mg. - morbus waldenström,; chronisch-lymphatische leukämie (cll),; follikuläres lymphom - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

beigene switzerland gmbh - tislelizumabum - 100 mg / 10 ml konzentrat zur herstellung einer infusionslösung - tislelizumabum 100 mg, natrii citras dihydricus, acidum citricum monohydricum, histidini hydrochloridum monohydricum, histidinum, trehalosum dihydricum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 10 ml corresp. natrium 16 mg. - onkologikum - biotechnologika

Union européenne - français - EMA (European Medicines Agency)

novartis europharm limited - tislelizumab - esophageal squamous cell carcinoma - agents antinéoplasiques - oesophageal squamous cell carcinoma (oscc) tevimbra as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy.

Union européenne - français - EMA (European Medicines Agency)

celgene europe bv - azacitidine - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - agents antinéoplasiques - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.

Union européenne - français - EMA (European Medicines Agency)

celgene europe ltd. - lepirudin - thromboembolism; thrombocytopenia - agents antithrombotiques - anticoagulation chez les patients adultes atteints de thrombocytopénie de type ii induite par l'héparine et d'une maladie thromboembolique nécessitant un traitement antithrombotique par voie parentérale. le diagnostic doit être confirmé par l'héparine-induite par l'activation plaquettaire test ou un test équivalent.

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

norbrook laboratories (ireland) ltd. - marbofloxacine 3 mg/ml; clotrimazole 10 mg/ml; acétate de dexaméthasone 1 mg/ml - eq. dexaméthasone 0,9 mg/ml - suspension auriculaire en gouttes - marbofloxacine 3 mg/ml; clotrimazole 10 mg/ml; acétate de dexaméthasone 1 mg/ml - dexamethasone and antiinfectives - chien

France - français - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

celgene france - thalidomide - gélule

Union européenne - français - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - la thalidomide - le myélome multiple - immunosuppresseurs - thalidomide bms in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy. thalidomide bms is prescribed and dispensed according to the thalidomide celgene pregnancy prevention programme (see section 4.